Skip to main content
Equibles
DXCM logo

DXCM · Dexcom Inc · Metrics

Track DXCM — free

Use DXCM with AI

Add company filings, earnings and prices to ChatGPT or Claude, then ask questions in your own chat.

Choose your app for step-by-step connection instructions. Sign in with Equibles when asked; no code or API key is needed.

Claude ChatGPT

After connecting, ask your AI to use Equibles to research DXCM.

Other apps & server URL
https://mcp.equibles.com/mcp
Gemini CLI setup
or ask here

Free, nothing to set up — ALVIS runs on the same tools and cites every figure.

See what you can ask in ChatGPT or Claude

All connection guides →
$77.94 -0.38 (-0.49%) At close · Oct 23
S&P 500 member Nasdaq-100 member Russell 1000 member Rebalance outlook locked
Market Cap
$29.41B
Shares
377.36M
Volume · Oct 23 5.22M Avg daily vol (3M) 4.51M

DXCM metrics

110 of 122 screener metrics currently available.

Open in screener

Market overview

2 metrics
Share price
$77.94
Market cap
$29.41B

Price action

20 metrics
Price change (1W)
-9.4%
Price change (30D)
-11.2%
Price change (3M)
+8.9%
Price change (6M)
+26.6%
Price change (YTD)
+17.4%
Price change (1Y)
+9.7%
Trailing year
Price change (5Y)
—
52-week high
$92.34
52-week low
$54.84
Change from 52-week high
-15.6%
Change from 52-week low
+42.1%
Annualized volatility
40.3%
Annualized volatility (3M)
39.4%
Beta
0.6
RSI (14D)
32.1
Price vs SMA 50
-10.2%
Price vs SMA 200
+4.9%
Avg volume (3M)
4.51M
Relative volume
1.2
Average dollar volume
$385.67M

Company

3 metrics
Sector
Healthcare
Industry
Medical Devices
Shares outstanding
377.36M

Valuation

12 metrics
P / E (TTM)
30.9
Trailing earnings · reciprocal yield 3.2%
PEG ratio
0.7
EV / revenue
6.0×
reciprocal yield 16.7%
EV / EBITDA
21.2×
reciprocal yield 4.7%
EV / EBIT
26.1×
reciprocal yield 3.8%
P / sales
5.9×
reciprocal yield 16.8%
P / book
11.3
reciprocal yield 8.9%
FCF yield
4.8%
TTM · current market cap
Buyback yield
3.7%
P / FCF
21.0
reciprocal yield 4.8%
P / operating cash flow
16.9
reciprocal yield 5.9%
Earnings yield
3.4%

Historical valuation

8 metrics
P / E historical average (3Y)
57.6×
reciprocal yield 1.7%
P / E historical average (5Y)
96.0×
reciprocal yield 1.0%
EV / revenue historical average (3Y)
8.7×
reciprocal yield 11.5%
EV / revenue historical average (5Y)
11.4×
reciprocal yield 8.8%
EV / EBIT historical average (3Y)
51.9×
reciprocal yield 1.9%
EV / EBIT historical average (5Y)
77.9×
reciprocal yield 1.3%
EV / EBITDA historical average (3Y)
36.3×
reciprocal yield 2.8%
EV / EBITDA historical average (5Y)
54.8×
reciprocal yield 1.8%

Dividends & buybacks

7 metrics
Dividend yield
—
Trailing 12 months
Payout ratio
—
Shareholder yield
3.7%
Dividend / share (TTM)
—
Dividend growth YoY
—
Dividend growth streak
—
Last ex-dividend
—

Earnings calendar

2 metrics
Next earnings
—
Last earnings
2026-07-30

Profitability

9 metrics
Gross margin
62.5%
Operating margin
22.9%
Trailing 12 months
Net margin
20.1%
Gross profit (TTM)
$3.10B
Operating profit (TTM)
$1.14B
Net income (TTM)
$999.70M
Trailing 12 months
Diluted EPS (TTM)
$2.52
FCF margin
28.3%
Effective tax rate
21.9%

Per share

11 metrics
Revenue per diluted share (TTM)
$12.51
Gross profit per diluted share (TTM)
$7.82
Operating profit per diluted share (TTM)
$2.87
EBITDA per diluted share (TTM)
$3.53
Net income per diluted share (TTM)
$2.51
Operating cash flow per diluted share (TTM)
$4.38
Free cash flow per diluted share (TTM)
$3.52
Capital expenditures per diluted share (TTM)
$0.86
R&D per diluted share (TTM)
$1.52
Stock compensation per diluted share (TTM)
$0.41
Book value per share
$7.14

Growth

11 metrics
Revenue growth YoY
+13.1%
Year over year
Net income growth YoY
+38.5%
Revenue (TTM)
$4.97B
Trailing 12 months
EPS growth YoY
+42.2%
Shares change YoY
-4.4%
Year over year · fewer shares
Revenue CAGR (3Y)
+17.0%
Revenue CAGR (5Y)
+19.3%
EPS CAGR (3Y)
+36.6%
EPS CAGR (5Y)
+9.5%
FCF CAGR (3Y)
+52.3%
FCF CAGR (5Y)
+31.2%

Quality

14 metrics
Return on equity
38.1%
Return on assets
15.5%
Debt / equity
0.5
Current ratio
1.7
EBITDA (TTM)
$1.40B
Free cash flow (TTM)
$1.41B
Quick ratio
1.4
Interest coverage
75.9
Net debt / EBITDA
0.1
Return on invested capital
32.2%
Trailing 12 months
Net cash
−$137.80M
Latest balance sheet
Cash & equivalents
$1.10B
Total assets
$6.46B
Total debt
$1.24B

Cash flow & spend

7 metrics
Operating cash flow (TTM)
$1.75B
Capital expenditures (TTM)
$343.70M
R&D (TTM)
$604.00M
SG&A (TTM)
$1.36B
Stock compensation (TTM)
$162.40M
R&D / revenue
12.2%
Stock compensation / revenue
3.3%

Ownership (13F)

9 metrics
13F filers
983
13F filer change QoQ
+15
Institutional ownership
104.7%
Conviction holders (share of 13F filers)
0.6%
Crowding (high-turnover and private-fund holders)
—
Private-fund adviser ownership
—
Active holders' share change QoQ
+5.1%
Holder tenure
17.8
Price vs estimated holder cost
-8.2%

Ownership (registered funds)

1 metrics
Index-fund ownership
24.1%

Short interest

3 metrics
Short interest
3.7%
Latest settlement · 3.2 days to cover
Days to cover
3.2d
Short-squeeze score
48 / 100

Insider activity

2 metrics
Net insider buying (90D)
−$4.70M
Insider-sentiment score
—

Risk flags

1 metrics
Going concern
—
Key facts CIK 1093557 CUSIP 252131107 13F (30d) 214 filings 208 filers Visit website Investor relations